Free Trial

Ocular Therapeutix (OCUL) News Today

Ocular Therapeutix logo
$7.30 +0.08 (+1.11%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$7.14 -0.16 (-2.18%)
As of 05/23/2025 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OCUL Latest News

Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of "Moderate Buy" from Brokerages
Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to th
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Deutsche Bank AG
Deutsche Bank AG lessened its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 45.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 456,120 shares of the biopharmaceutical company's s
Ocular Therapeutix, Inc. stock logo
Graham Capital Management L.P. Takes $321,000 Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Graham Capital Management L.P. acquired a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 37,577 shares of the biopharmaceutical company's st
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Bought by Second Line Capital LLC
Second Line Capital LLC boosted its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 29.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 340,098 shares of the bio
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Bought by Point72 Asset Management L.P.
Point72 Asset Management L.P. increased its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 43.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,935,924 shares of the biopharmaceutical
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Holdings Boosted by Northern Trust Corp
Northern Trust Corp boosted its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 5.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,314,871 shares of the biopharmaceutical company's stock af
Ocular Therapeutix, Inc. stock logo
Polar Asset Management Partners Inc. Trims Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Polar Asset Management Partners Inc. cut its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 20.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 394,400 shares of the biopharmaceutical company
Ocular Therapeutix, Inc. stock logo
Balyasny Asset Management L.P. Acquires New Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Balyasny Asset Management L.P. acquired a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 97,553 shares of the biopharmaceutical company's stock, valued
Ocular Therapeutix, Inc. stock logo
Patient Square Capital LP Raises Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Patient Square Capital LP lifted its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 100.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 470,919 shares of the biopharma
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock Holdings Boosted by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 22.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 270,422 shares of the biopharmaceutical company's s
Ocular Therapeutix, Inc. stock logo
Richard L. Md Lindstrom Purchases 10,000 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock
Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) Director Richard L. Md Lindstrom purchased 10,000 shares of the company's stock in a transaction on Thursday, May 8th. The shares were bought at an average price of $6.96 per share, with a total value of $69,600.00. Following the completion of the transaction, the director now owns 172,704 shares of the company's stock, valued at approximately $1,202,019.84. The trade was a 6.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.
Ocular Therapeutix, Inc. stock logo
HC Wainwright Expects Weaker Earnings for Ocular Therapeutix
Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Equities research analysts at HC Wainwright lowered their Q2 2025 earnings per share estimates for Ocular Therapeutix in a research note issued to investors on Tuesday, May 6th. HC Wainwright analyst Y. Chen now forecasts that the biopharmace
Ocular Therapeutix, Inc. stock logo
William Blair Cuts Earnings Estimates for Ocular Therapeutix
Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Investment analysts at William Blair lowered their Q2 2025 EPS estimates for shares of Ocular Therapeutix in a research note issued on Monday, May 5th. William Blair analyst L. Hanbury-Brown now expects that the biopharmaceutical company will
Ocular Therapeutix, Inc. stock logo
What is HC Wainwright's Forecast for OCUL FY2026 Earnings?
Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Research analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for shares of Ocular Therapeutix in a research note issued to investors on Tuesday, May 6th. HC Wainwright analyst Y. Chen expects that the biopharmaceu
Ocular Therapeutix, Inc. stock logo
Deep Track Capital LP Grows Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Deep Track Capital LP increased its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 0.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,836,282 shares of the biopharmaceutical company's stock after
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix (NASDAQ:OCUL) Trading Down 6.5% on Analyst Downgrade
Ocular Therapeutix (NASDAQ:OCUL) Shares Down 6.5% Following Analyst Downgrade
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix (NASDAQ:OCUL) Price Target Cut to $14.00 by Analysts at Needham & Company LLC
Needham & Company LLC reduced their price target on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating for the company in a report on Tuesday.
Ocular Therapeutix, Inc. stock logo
212,944 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Acquired by First Trust Advisors LP
First Trust Advisors LP bought a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 212,944 shares of the biopharmaceutical company's stock, v
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Down - What's Next?
Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Down - Time to Sell?
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix (NASDAQ:OCUL) Announces Quarterly Earnings Results
Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.09). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%.
Ocular Therapeutix, Inc. stock logo
Aptus Capital Advisors LLC Has $2.90 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Aptus Capital Advisors LLC raised its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 29.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 339,750 shares of the biopharmaceutical company's stock after acquiring an additional 7
Ocular Therapeutix, Inc. stock logo
Price T Rowe Associates Inc. MD Has $5.46 Million Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Price T Rowe Associates Inc. MD cut its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 34.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 638,964 shares of the biopharmaceutical company's s
Ocular Therapeutix, Inc. stock logo
Voya Investment Management LLC Has $3.17 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Voya Investment Management LLC raised its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 35.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 371,235 shares of the biopharmaceutical company's stock after buying an additional 97,6
Ocular Therapeutix, Inc. stock logo
Wells Fargo & Company MN Has $634,000 Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Wells Fargo & Company MN lessened its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 83.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 74,208 shares of the biopharmaceut
Ocular Therapeutix, Inc. stock logo
Acuta Capital Partners LLC Has $9.49 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Acuta Capital Partners LLC lessened its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 6.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,111,071 shares of the biopharmaceutical company's stock after se
Ocular Therapeutix, Inc. stock logo
Raymond James Financial Inc. Takes Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Raymond James Financial Inc. purchased a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 201,623 shares of the biopharmaceutical company's sto
Ocular Therapeutix, Inc. stock logo
Barclays PLC Reduces Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Barclays PLC lessened its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 35.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 331,242 shares of the biopharmaceutical company's stock after selling 180,280 s
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix (OCUL) Projected to Post Quarterly Earnings on Tuesday
Ocular Therapeutix (NASDAQ:OCUL) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-ocular-therapeutix-inc-stock/)
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix (NASDAQ:OCUL) Trading Up 5.4% - What's Next?
Ocular Therapeutix (NASDAQ:OCUL) Trading 5.4% Higher - Here's What Happened
Ocular Therapeutix, Inc. stock logo
Nantahala Capital Management LLC Sells 262,272 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Nantahala Capital Management LLC decreased its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 37.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 437,728 shares of the b
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Adage Capital Partners GP L.L.C.
Adage Capital Partners GP L.L.C. decreased its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 4.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,600,000 shares of the biopharmaceutic
Ocular Therapeutix, Inc. stock logo
JPMorgan Chase & Co. Has $1.62 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
JPMorgan Chase & Co. grew its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 123.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 189,295 shares of the biopharmaceutical company's stock after acquiring an additio
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) have been given an average rating of "Moderate Buy" by the nine research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and eight have i
Ocular Therapeutix, Inc. stock logo
Invesco Ltd. Acquires 134,573 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Invesco Ltd. lifted its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 17.8% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 890,046 shares of the biopharmaceutical company's stock after acquiring an additional 134,573 shares du
Ocular Therapeutix, Inc. stock logo
Ocular Therapeutix (NASDAQ:OCUL) Stock Price Up 5.8% - Should You Buy?
Ocular Therapeutix (NASDAQ:OCUL) Shares Up 5.8% - Here's What Happened
Ocular Therapeutix, Inc. stock logo
Geode Capital Management LLC Has $27.64 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Geode Capital Management LLC cut its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 1.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,236,312 shares of the biopharmaceutical company's st
Get Ocular Therapeutix News Delivered to You Automatically

Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.

OCUL Media Mentions By Week

OCUL Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

OCUL
News Sentiment

1.53

0.75

Average
Medical
News Sentiment

OCUL News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

OCUL Articles
This Week

8

5

OCUL Articles
Average Week

Get Ocular Therapeutix News Delivered to You Automatically

Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:OCUL) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners